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134Bone marrow aspirate injection for treatment of
critical limb ischemia with comparison to patients
undergoing high-risk bypass grafts
Kristina A. Giles, MD, Eva M. Rzucidlo, MD, Philip P. Goodney, MD, MS, Daniel B. Walsh, MD, and
Richard J. Powell, MD, Lebanon, NH
Objective: Bone marrow cell therapy (BMCT) for patients with critical limb ischemia (CLI) is a potential treatment in
candidates with poor options for standard revascularization procedures. Whereas clinical trials are ongoing, there are few
comparative data to assess its efﬁcacy compared with bypass.
Methods: Patients with poor revascularization options underwent BMCT between 2011 and 2013. Outcomes were
compared with those of a cohort of CLI patients undergoing infrainguinal bypass thought to be at high risk for graft
failure (tissue loss, a tibial target, and a previous endovascular treatment or bypass). BMCT patients underwent harvest of
bone marrow that was then concentrated and injected intramuscularly into the ischemic limb.
Results: There were 20 BMCT patients and 35 high-risk bypass patients. All BMCT patients had either rest pain (80%) or tissue
loss (80%). The majority (65%) had a prior intervention (bypass, 30%; endovascular, 58%) compared with high-risk bypass
patients, all of whom had previous revascularization attempts (bypass, 43% [P [ .35]; endovascular, 77% [P [ .14]). Mean
follow-up was 773 days after BMCT and 972 days after high-risk bypass. All patients tolerated BMCT without issues or
complications. A second BMCT treatment was performed in 21% because of clinical deterioration. Wound healing occurred in
75% at 1.5 years, including patients receiving second injections, all of which resolved. Rest pain improved in 87.5% of patients.
Pain completely resolved in 58% at 1.5 years. Ankle-brachial index improvement was 0.23 (60.25). Three BMCT patients went
on to amputation. One-year freedom frommajor amputation or death was 78% for BMCT vs 69% for high-risk bypass (P[ .60).
Conclusions: BMCT is a potential option in CLI patients who are not candidates for bypass or endovascular intervention.
Limb salvage is unexpectedly high in this population with few other options. (J Vasc Surg 2015;61:134-7.)Critical limb ischemia (CLI) is the most severe form of
peripheral vascular disease and affects between 800,000
and 1,200,000 Americans.1 Standard treatment options
are based on some form of revascularization strategy by
either endovascular or open surgical approaches. A signiﬁ-
cant percentage of patients with CLI are not candidates for
revascularization because of anatomic or medical con-
straints. Endovascular therapy may not be possible in these
“no-option” CLI patients because of extensive or calciﬁed
multilevel disease, and open surgery may be precluded in
patients with an absent distal target or absent conduit.
The presence of medical comorbidities, such as congestive
heart failure or severe chronic kidney disease, may also
preclude attempts at revascularization because of surgicalthe Section of Vascular and Endovascular Surgery, Department of
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://dx.doi.org/10.1016/j.jvs.2014.06.089risk. An even larger cohort of CLI patients exist who are
“poor-option” patients for revascularization because of
suboptimal conduit or distal target and medical comorbid-
ities that make surgery high risk.
In patients presenting with CLI who are not suitable
candidates for revascularization, outcomes may be highly
variable, depending on clinical presentation. Studies have
shown that major amputation within 1 year can be expected
in 5% to 15% of patients presenting with rest pain and 30% to
40% of patients who present with tissue loss.2,3 There are
currently no medical therapies for CLI approved by the
Food and Drug Administration. Recent focus has been
placed on biologic therapies that include gene therapy and
cellular therapy, which offer the potential to promote wound
healing and to prevent amputation in patients who otherwise
have no options for revascularization.4-7 These treatment
modalities may promote therapeutic angiogenesis, which is
deﬁned as the growth of new blood vessels from pre-
existing blood vessels in response to growth factor stimula-
tion. This has been shown to occur in animal models of
hind limb ischemia and can be induced by cellular therapy
with stem cells or bone marrow aspirate. There have been
several phase 2 clinical trials that have demonstrated prom-
ising outcomes in patients with CLI compared with pla-
cebo.8-10 This was especially true in patients who presented
with tissue loss.3 These trials have used a single set of intra-
muscular injections of autologous cells obtained from either
bone marrow harvest or expanded cell lines after aspiration.
Table. Demographics of patients undergoing bone
marrow cell therapy (BMCT) and high-risk bypass
BMCT
(n ¼ 20)
Bypass
(n ¼ 35) P value
Age 72.7 6 13.5 69.5 6 9.8 .32
Male 60% 65% .73
Current smoking 15% 37% .08
Any smoking 90% 83% .47
Hypertension 85% 86% .94
Diabetes 45% 71% .05
Coronary disease 70% 37% .02
CHF 40% 14% .03
COPD 15% 54% .005
Creatinine, mg/dL 1.1 6 0.4 1.1 6 0.4 .73
Aspirin 85% 94% .25
Clopidogrel 15% 17% .84
Statin 70% 69% .91
Previous intervention 65% 100% <.001
PTA/stent 58% 77% .14
Bypass 30% 43% .35
Tissue loss or rest pain 100% 100% .99
Preoperative ABI 0.45 6 0.2 0.51 6 0.3 .53
Preoperative TBI 0.10 6 0.9 0.23 6 0.3 .04
ABI, Ankle-brachial index; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; PTA, percutaneous transluminal angioplasty;
TBI, toe-brachial index.
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experience in the treatment of poor- or no-option CLI pa-
tients with bone marrow aspirate concentrate and the use
of re-treatment when it is clinically indicated.
METHODS
Patients with hemodynamically conﬁrmed CLI mani-
fested with either tissue loss or nocturnal metatarsalgia
who were not deemed to be suitable candidates for either
open or endovascular revascularization by their vascular
surgeon were offered autologous bone marrow cell therapy
(BMCT). Patients with active malignant disease, bone
marrow dysplastic syndrome, or immunosuppressive ther-
apy were not treated. This study was approved by and com-
plied with the Institutional Review Board at the Geisel
School of Medicine and Dartmouth Hitchcock Medical
Center. All patients gave full consent for research study
participation.
After informed consent was obtained from the patient,
BMCT was performed in the operating room under local
anesthesia with conscious sedation. The patient was placed
prone, and 120 to 240 mL of bone marrow was aspirated
under sterile condition from the bilateral posterior iliac crests.
The amount of bone marrow aspirated was based on the size
and frailty of the patient. The bone marrow was then
concentrated by the Emcyte (Fort Meyers, Fla) cell prepara-
tion system, which consists of a centrifuge that rotates at
2000 rpm for 15 minutes. Plasma was then discarded, and
the cellular component was collected and injected intramus-
cularly in 1-mL increments into the ischemic leg in at least
40 locations based on a standardized grid. Injections were
placed below the knee and between the web spaces in the
foot. Patients were discharged the same day.
Patients were observed as clinically appropriate so that pa-
tients with wounds had more frequent follow-up visits than
did patients who presented with rest pain. Wound care was
at the discretion of the referring vascular surgeon. Patients
who had clinical improvement after the initial set of injections
but who either subsequently deteriorated or failed to
continue to improve were offered a second treatment.
The group of BMCT patients were compared with a
group of CLI patients at our institution who had poor op-
tions for open surgery and subsequently underwent a
bypass that was at high risk for failure. The high-risk bypass
cohort was deﬁned as patients undergoing lower extremity
bypass who had tissue loss, a tibial target, and a previously
attempted lower extremity vascular intervention. In addi-
tion, the cell therapy group was compared with the 1-
year amputation-free survival (AFS) objective performance
goal for CLI recently published by a writing group from
the Society for Vascular Surgery.11
Patients underwent minor or major amputation as clin-
ically indicated for progressive tissue loss, infection, or un-
remitting rest pain.
The outcome variables that were assessed included
AFS, complete wound healing, and resolution of rest
pain. AFS was deﬁned as freedom from all-cause death
and any amputation above the ankle. Complete woundhealing was deﬁned as all wounds on the affected foot hav-
ing healed for a minimum of 2 weeks.
Statistical analysis. Results were analyzed by STATA
statistical software (Stata 12.1; StataCorp, College Station,
Tex). Categorical and continuous variables were analyzed
with c2 and Student t-tests, respectively. Survival analyses
were performed by Kaplan-Meier methodology. Statistical
signiﬁcance was deﬁned as P < .05.
RESULTS
A total of 20 patients were treated with BMCT be-
tween 2011 and 2013 and had a mean follow-up of
521 6 220 days. Prior endovascular revascularization pro-
cedures had been attempted in 58% and prior bypasses in
30% (Table).
Thirty ﬁve patients within our database underwent a
high-risk bypass that met our previously deﬁned criteria.
Bypass patients had a mean follow-up of 972 6
854 days. Prior endovascular revascularization procedures
had been attempted in 77% of bypass patients, and 43%
had previously attempted bypasses.
The demographics for the BMCT and high-risk bypass
groups are shown in the Table. The BMCT group had a
higher proportion of patients with coronary artery disease
and congestive heart failure; the high-risk bypass group
had a higher proportion of patients with chronic obstructive
pulmonary disease. Age and the remaining comorbidities
were similar between groups. Preoperative ankle-brachial
indices were similar between groups (0.45 vs 0.51; P ¼
.53), whereas preoperative toe-brachial indices were lower
in the BMCT cohort (0.10 vs 0.23; P ¼ .04).
The majority of patients (85%) had BMCT performed
as an outpatient procedure. All patients tolerated both the
Fig 1. Amputation-free survival (AFS) after bone marrow cell
therapy (BMCT) and high-risk bypass. NS, Not signiﬁcant.
Fig 2. Wound healing after bone marrow cell therapy (BMCT).
Fig 3. Complete resolution of rest pain after bone marrow cell
therapy (BMCT).
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minor or major procedure-related complications after
BMCT. There were no 30-day deaths. Only two patients
(10%) had a survival of less than 1 year. During follow-
up, the death of one patient was due to vascular related
events, with death occurring after a below-knee
amputation.
Minor amputations were performed in 30% of BMCT
patients. Major amputation occurred in 20% of BMCT pa-
tients and 20% of high-risk bypass patients. AFS is shown in
Fig 1. At 1 year, AFS for the BMCT cohort was 78%
compared with 69% for the high-risk bypass cohort (P ¼
.60). Objective performance goal measures set the efﬁcacy
outcome at 71% for high-risk conduit and 68% for
anatomic high-risk cohorts.
The effect of BMCT on wound healing is shown in
Fig 2, with a 75% rate of complete wound healing at
1.5 years. As shown in Fig 3, resolution of rest pain closely
followed the same time course of wound healing after
BMCT, with most patients experiencing complete resolu-
tion within 9 months. Four patients underwent repeated
bone marrow harvest and injection for continued wounds
after their ﬁrst injection. All had ultimate complete wound
healing or rest pain resolution after the repeated injections.
The mean ankle-brachial index increase was 0.23 6
0.25 after BMCT vs 0.25 6 0.4 after high-risk bypass
(P ¼ .9).
DISCUSSION
In the current series of CLI patients with poor options
for standard revascularization who underwent BMCT, the
AFS at 1 year was 78%. This would meet the Society for
Vascular Surgery CLI objective performance goal for AFS
at 1 year, which is 71%.11 In addition, the BMCT patients
had an AFS comparable to that of a similar cohort of CLI
patients who underwent high-risk lower extremity bypass.
It is acknowledged that neither the Society for Vascular
Surgery objective performance goals cohort nor the high-
risk bypass cohort is identical to the patients included in
this report. Because this was not a clinical trial and thereis no placebo group, we used the additional patient groups
to help place our ﬁndings of BMCT therapy in perspective.
The use of concentrated bone marrow aspirate was
initially described by Tateishi-Yuyama et al.12 These inves-
tigators demonstrated an increase in ankle-brachial index in
patients treated with BMCT compared with patients
treated with peripheral blood injections. Subsequent
work by Franz et al demonstrated similar ﬁndings.13 Our
ﬁndings in the current study are similar to those of several
phase 2 cell therapy clinical trials that have been recently re-
ported. The Harvest Trial collected 240 mL of bone
marrow that was concentrated and injected into the
ischemic extremity, similar to that in this report.8 These in-
vestigators found that freedom from major amputation in
patients who presented with tissue loss was 61% in cell ther-
apy patients vs 29% in placebo-treated patients. The
RESTORE-CLI trial randomized patients to expanded
autologous cell therapy vs placebo in no-option CLI pa-
tients9,10; 50 mL of bone marrow was harvested, and cells
were then sent to the sponsor, who expanded speciﬁc cell
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returned to the site and injected into the limb. In this trial,
freedom from major amputation at 1 year was 81% in the
cell therapy patients vs 67% in the placebo-treated patients.
A novel feature of the current report is that patients
who initially showed clinical response based on wound
healing or decrease in rest pain but who then deteriorated
were offered re-treatment. Of the four patients who under-
went re-treatment, all had complete wound healing, and no
amputations occurred in this group. This may have signif-
icant implications for future cell therapy paradigms. CLI
is a progressive unrelenting disease process, and it may
not be realistic to expect that a single treatment with cell
therapy will have a durable clinical response. The ﬁndings
in the current study support this concept in that patients
who were redosed had more favorable outcomes at longer
than 1 year.
The current report also demonstrates that BMCT is
well tolerated in this group of patients with a high comor-
bid burden. The majority of the procedures were per-
formed on an ambulatory basis. The 30-day death/
complication/readmission rate was low. There were no
periprocedural deaths, and there was no evidence to sug-
gest that patients manifested evidence of off-target angio-
genesis, such as progression of diabetic retinopathy.
This report demonstrates the safety and utility of
BMCT with selected re-treatment in patients with CLI
who are not good candidates for open revascularization
and have no endovascular option. This group of patients
is at moderate to high risk for limb loss and the attendant
consequences that this has on independence, quality of life,
and rehabilitation potential. However, this report suffers
from several acknowledged shortcomings, which include
a lack of an appropriate control group and that the treat-
ment was not blinded. The knowledge that all patients
received BMCT could bias the treating surgeon toward
more aggressive wound care. An additional shortcoming
is a lack of complete hemodynamic follow-up. However,
hemodynamic parameters do not correlate closely with
symptom status in peripheral vascular disease, and it is
possible that BMCT can affect wound healing and limb
salvage without having an appreciable effect on ankle-
brachial index or toe pressure.
CONCLUSIONS
BMCT is a reasonable option for patients with CLI
who otherwise have no revascularization potential.
Vascular surgeons should consider this treatment modality
in selected patients.
AUTHOR CONTRIBUTIONS
Conception and design: KG, ER, RP
Analysis and interpretation: KG, ER, PG, DW, RP
Data collection: KG, ER, RPWriting the article: KG, RP
Critical revision of the article: KG, ER, PG, DW, RP
Final approval of the article: KG, RP
Statistical analysis: KG, RP
Obtained funding: ER, RP
Overall responsibility: RPREFERENCES
1. Baser O, Verpillat P, Gabriel S, Wang L. Prevalence, incidence, and
outcomes of critical limb ischemia in the US Medicare population. Vasc
Dis Manag 2013;10:26-36.
2. Benoit E, O’Donnell TF Jr, Kitsios GD, Iafrati MD. Improved
amputation-free survival in unreconstructable critical limb ischemia and
its implications for clinical trial design and quality measurement. J Vasc
Surg 2012;55:781-9.
3. Benoit E, O’Donnell T, Iafrati M, Asher E, Bandyk D, Hallett J, et al.
The role of amputation as an outcome measure in cellular therapy for
critical limb ischemia: implications for clinical trial design. J Transl Med
2011;9:165.
4. Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous
bone marrow cell transplantation increases leg perfusion and reduces
amputations in patients with advanced critical limb ischemia due to
peripheral artery disease. Cell Transplant 2009;18:371-80.
5. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for
peripheral arterial disease: meta-analysis and systematic review of the
literature. Atherosclerosis 2010;209:10-7.
6. Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH; HGF-
0205 Trial Investigators. Safety and efﬁcacy of patient speciﬁc intra-
muscular injection of HGF plasmid gene therapy on limb perfusion and
wound healing in patients with ischemic lower extremity ulceration:
Results of the HGF-0205 trial. J Vasc Surg 2010;52:1525-30.
7. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry T, Koga M,
et al. Results of a double-blind, placebo-controlled study to assess the
safety of intramuscular injection of hepatocyte growth factor plasmid to
improve limb perfusion in patients with critical limb ischemia. Circu-
lation 2008;118:58-65.
8. Iafrati M, Bandyk D, Benoit E, Geils G, Hallett J, Hingorani A, et al.
Bone marrow aspirate concentrate in critical limb ischemia: results of a
multicenter randomized double blind trial. J Vasc Surg 2010;52:11.
9. Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E,
et al. Interim analysis results from the RESTORE-CLI, a randomized,
double-blind multicenter phase II trial comparing expanded autolo-
gous bone marrowederived tissue repair cells and placebo in patients
with critical limb ischemia. J Vasc Surg 2011;54:1032-41.
10. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD,
Longcore AT, et al. Cellular therapy with Ixmyelocel-T to treat critical
limb ischemia: the randomized, double-blind, placebo-controlled
RESTORE-CLI trial. Mol Ther 2012;20:1280-6.
11. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested objective performance goals and clinical
trial design for evaluating catheter-based treatment of critical limb
ischemia. J Vasc Surg 2009;50:1462-73.e1-3.
12. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S,
Masaki H, et al. Therapeutic angiogenesis for patients with limb
ischemia by autologous transplantation of bone-marrow cells: a pilot
study and a randomized controlled trial. Lancet 2002;360:427-35.
13. Franz RW, Shah KJ, Johnson JD, Pin RH, Parks AM, Hankins T, et al.
Short- to mid-term results using autologous bone-marrow mono-
nuclear cell implantation therapy as a limb salvage procedure in patients
with severe peripheral arterial disease. Vasc Endovascular Surg
2011;45:398-406.
Submitted Mar 6, 2014; accepted Jun 11, 2014.
